Search

everythinglearnresearchcommunity

for

Search:↓

Dutasteride effectively treats benign prostatic obstruction, improves urinary flow, reduces prostate size, and may prevent prostate cancer, but can cause sexual side effects.

After chemotherapy for early breast cancer, 33.4% of patients had long-term significant hair loss, with some hair regrowth over time, but treatments for hair loss were largely ineffective.

The document suggests that clinical trials for PCOS should focus on meaningful primary outcomes like live birth rates, rather than less reliable surrogate markers.

5α-reductase inhibitors may prevent prostate cancer but could also raise the risk of more severe cancers.

Inhibiting 5α-reductase can help reduce prostate cancer risk and improve treatment.

Finasteride might lower the risk of low-grade prostate cancer but not high-grade cancer, while alpha-blockers might reduce high-grade cancer risk.

Late puberty may slightly lower prostate cancer risk, baldness is not linked to overall risk but less so with aggressive types, ibuprofen use may increase risk, and vitamins show no effect on risk.

CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.

Taking 1 mg/day finasteride for hair loss significantly lowers PSA levels in men, which may affect prostate cancer screening.

Scalp cooling effectively reduces hair loss from chemotherapy.

5-Alpha reductase inhibitors are safe long-term but may be outdated for preventing less significant prostate cancer.

Men's hair loss is caused by hormones and genes, and can be treated with medication and surgery, while graying is due to aging and has no prevention except dyeing.

5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.

Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.

Cancer survivors often experience worse skin problems from treatment than expected, and working with dermatologists could help improve their condition.

No treatment showed significant long-term hair growth benefits for alopecia areata.

Large prostates link to more hair loss.

Dutasteride and finasteride do not significantly affect bone density, blood fats, or blood production, but slightly lower PSA levels and minimally impact sexual function in healthy young men.

Men taking 5α-reductase inhibitors for enlarged prostate have a higher chance of experiencing reduced sexual desire and erectile dysfunction.

Finasteride significantly reduces PSA levels in men, and doctors should adjust PSA readings for those taking the drug.

Dutasteride effectively treats enlarged prostate, reduces prostate cancer risk, and promotes hair regrowth with few side effects.

5-alpha-reductase inhibitors may cause a low incidence of erectile dysfunction that decreases over time.

Testosterone therapy can improve sexual desire and function in postmenopausal women but should be used cautiously and not based solely on testosterone levels.

Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.

The guideline provides healthcare professionals in South Africa with instructions for comprehensive, multidisciplinary gender-affirming care, including HIV prevention and treatment for transgender and gender diverse individuals.

Finasteride for hair loss lowers PSA levels, so PSA values need adjusting when screening for prostate cancer.

Finasteride's link to health issues like male breast cancer, infertility, and prostate cancer needs more research through placebo-controlled trials to confirm.

Finasteride safely and effectively treats male pattern hair loss, but may cause reversible sexual issues and harm male fetuses.

The guidelines advise against using testosterone and DHEA in women for most conditions due to safety and effectiveness concerns, but suggest considering testosterone for postmenopausal women with low sexual desire.